Organon & Co. (OGN)

NYSE: OGN · IEX Real-Time Price · USD
18.80
+0.35 (1.90%)
At close: Mar 28, 2024, 4:00 PM
18.94
+0.14 (0.74%)
After-hours: Mar 28, 2024, 7:30 PM EDT

Company Description

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally.

Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.

It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.

The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss.

It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.

The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Organon & Co.
Organon & Co. logo
Country United States
Founded 1923
Industry Drug Manufacturers - General
Sector Healthcare
Employees 10,000
CEO Kevin Ali

Contact Details

Address:
30 Hudson Street, Fl 33
Jersey City, New Jersey 07302
United States
Phone 551-430-6000
Website organon.com

Stock Details

Ticker Symbol OGN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821825
CUSIP Number 68622V106
ISIN Number US68622V1061
Employer ID 46-4838035
SIC Code 2834

Key Executives

Name Position
Kevin Ali Chief Executive Officer and Director
Matthew M. Walsh Executive Vice President and Chief Financial Officer
Susanne Gabriele Fiedler Executive Vice President and Chief Commercial Officer
Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing and Supply
Rachel A. Stahler Executive Vice President and Chief Information Officer
Jennifer Halchak Head of Investor Relations
Kirke Weaver Executive Vice President, General Counsel and Corporate Secretary
Susan O'Neal Chief Ethics and Compliance Officer
Rebecca Lowell Edwards Chief Communications Officer
Daniel Karp Chief Business Development Officer

Latest SEC Filings

Date Type Title
Feb 26, 2024 10-K Annual Report
Feb 15, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 5, 2023 8-K Current Report
Nov 7, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 3, 2023 10-Q Quarterly Report
Nov 2, 2023 8-K Current Report